Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Does Using Fidaxomicin to Treat Clostridium Difficile Infection (CDI) Reduce the Recovery of C. Difficile From Patients' Faeces, Skin and Their Immediate Environment, Compared to Treatment With Vancomycin or Metronidazole?

NCT02461901 is registered in ClinicalTrials.gov with Professor Mark Wilcox as lead sponsor.

NCT NCT02461901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02461901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Does Using Fidaxomicin to Treat Clostridium Difficile Infection (CDI) Reduce the Recovery of C. Difficile From Patients' Faeces, Skin and Their Immediate Environment, Compared to Treatment With Vancomycin or Metronidazole?
Lead sponsor
Professor Mark Wilcox
Phase
Observational
Overall status
Completed
Start date
January 31, 2015
Completion date
December 31, 2017
Enrollment
203 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection